GSK · Pharma and healthcare · one day
GSK (GSK): news on Monday 9 November 2026
News from the 24 hours to Monday morning, 9 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by the planned closure of a German vaccine plant with 641 jobs at risk, which leans negative. Smaller items on an Indonesian regulator meeting and upcoming investor conferences were mildly positive or routine.
What drove it
- German plant closure
- Indonesia health partnership
- investor conferences
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Tue 3 Nov | +2.7 | 6 |
| Wed 4 Nov | +5.0 | 14 |
| Thu 5 Nov | +5.0 | 11 |
| Fri 6 Nov | +4.5 | 8 |
| Sat 7 Nov | +4.5 | 17 |
| Sun 8 Nov | +5.7 | 2 |
| Mon 9 Nov | −3.3 | 3 |
| Tue 10 Nov | +6.3 | 13 |
| Wed 11 Nov | +4.5 | 6 |
| Thu 12 Nov | +4.5 | 12 |
| Fri 13 Nov | +4.2 | 14 |
3 stories · 3 headlines · strongest first
Pharma and healthcare on 9 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK will shut vaccine plant in Germany −7.51 headline today · GSK plans to close a German vaccine plant, putting 641 jobs at risk. | ||
| −7.5 | Plant closure puts hundreds of jobs at risk, reflecting restructuring. | |
| GSK and BPOM discuss health science in Indonesia +2.51 headline today · GSK and Indonesia's BPOM discussed health science and innovation. | ||
| +2.5 | GSK engaged with Indonesian regulator on health science and innovation. | |
| GSK has two investor conferences coming up +2.71 headline today · 7 in all · GSK has a pair of investor conferences scheduled for the week ahead. | ||
| +0.8 | Upcoming investor conference appearances, mostly routine scheduling. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.